Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study
- PMID: 11003611
- DOI: 10.1053/jhep.2000.17894
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study
Abstract
It has recently been suggested that nonalcoholic steatohepatitis (NASH) is an under-recognized cause of cryptogenic cirrhosis (CC) on the basis of higher prevalence of obesity and type II diabetes among these patients. To test this hypothesis, we studied 65 consecutive patients with advanced cirrhosis (Child-Pugh Score >/= 7) of undetermined etiology (CC) from our active waiting list for liver transplantation in January 1993, 1996, and 1999. For each patient, we selected 2 age- and sex-matched controls from the corresponding lists. The prevalence of obesity (defined as body mass index [BMI] >/= 30) and diabetes were compared between the groups. Sixteen patients (and their 32 controls) with CC were excluded as further review of records suggested other possible etiologies. Thus, the final analysis included 49 patients and 98 controls. The etiology of cirrhosis in the control group was alcohol in 16.3%, chronic viral hepatitis in 30.6%, autoimmune hepatitis in 8.2%, and primary biliary cirrhosis (PBC) or primary sclerosing cholangitis in 35.7%. The prevalence of obesity (55% vs. 24%) and type II diabetes (47% vs. 22%) was significantly higher in patients with CC compared with controls. Twenty-three percent of patients with CC had both obesity and diabetes compared with 5% among controls (P =.002). There was no difference in the prevalence of hypercholesterolemia (serum cholesterol > 200 mg/dL) between the groups. In conclusion, patients with advanced CC are more likely to be obese and diabetic compared with age- and sex-matched patients with advanced cirrhosis. This supports the hypothesis that NASH may be an etiological factor in some of the patients with CC.
Similar articles
-
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.Hepatology. 1999 Mar;29(3):664-9. doi: 10.1002/hep.510290347. Hepatology. 1999. PMID: 10051466
-
Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan.Hepatogastroenterology. 2003 Nov-Dec;50(54):2005-8. Hepatogastroenterology. 2003. PMID: 14696453
-
Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis.Trop Gastroenterol. 2004 Jan-Mar;25(1):15-7. Trop Gastroenterol. 2004. PMID: 15303464
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
[Non-alcoholic fatty liver: 10 years' experience at the Insituto Nacional de la Nutrición Salvador Zubirán].Rev Invest Clin. 1994 Mar-Apr;46(2):85-92. Rev Invest Clin. 1994. PMID: 8052745 Review. Spanish.
Cited by
-
Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study.Intern Med. 2023 May 15;62(10):1415-1423. doi: 10.2169/internalmedicine.0514-22. Epub 2022 Sep 28. Intern Med. 2023. PMID: 36171128 Free PMC article.
-
From fatty liver to fibrosis: a tale of "second hit".World J Gastroenterol. 2013 Feb 28;19(8):1158-65. doi: 10.3748/wjg.v19.i8.1158. World J Gastroenterol. 2013. PMID: 23483818 Free PMC article. Review.
-
The Cause-and-Effect Relationship Between Type 2 Diabetes Mellitus and Clinically Overt Cryptogenic Cirrhosis: A Matter That Must Be Seriously Revised.Hepat Mon. 2016 Aug 16;16(9):e36485. doi: 10.5812/hepatmon.36485. eCollection 2016 Sep. Hepat Mon. 2016. PMID: 27822261 Free PMC article. No abstract available.
-
Cryptogenic cirrhosis in the region where obesity is not prevalent.World J Gastroenterol. 2006 Apr 7;12(13):2080-5. doi: 10.3748/wjg.v12.i13.2080. World J Gastroenterol. 2006. PMID: 16610061 Free PMC article.
-
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Diabetes Ther. 2021 Mar;12(3):843-861. doi: 10.1007/s13300-021-01011-3. Epub 2021 Feb 14. Diabetes Ther. 2021. PMID: 33586120 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical